Adlbrecht, C. and Wild, C. (2010): Radionuclide therapy - 90Yttrium and 177Lutetium somatostatin analogues for the treatment of inoperable neuroendocrine tumors. Decision Support Document 40.

Auinger, D. (2022): Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for secondary peritoneal carcinomatosis: 1st Update. Decision Support Document 74/ Update 2022.

Auinger, D. and Sehic, O. (2023): Update PET/PET-CT evidence for need based planning in the area of oncology. AIHTA Policy Brief 003/ 3. Update.

Baumann, M. and Grössmann, N. (2016): Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 58.

Breuer, J. and Joppi, R. and Poggiani, C. and Dabrowska, M. and Zawodnik, A. and Nachtnebel, A. (2014): Obinutuzumab (Gazyva®) for previously untreated patients with chronic lymphocytic leukaemia (CLL). DSD: Horizon Scanning in Oncology 45.

Breuer, J. and Joppi, R. and Poggiani, C. and Polkowska, M. and Nachtnebel, A. (2014): Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. DSD: Horizon Scanning in Oncology 44.

Breuer, J. and Nachtnebel, A. (2014): Horizon Scanning in Oncology: Results of the 20th Prioritisation – 3rd quarter 2014. HSO: 20th Prioritisation.

Breuer, J. and Nachtnebel, A. (2014): Horizon Scanning in Oncology: Results of the 19th Prioritisation – 2nd quarter 2014. HSO: 19th Prioritisation.

Breuer, J. and Nachtnebel, A. (2014): Horizon Scanning in Oncology: Results of the 18th Prioritisation – 1st quarter 2014. HSO: 18th Prioritisation.

Breuer, J. and Nachtnebel, A. (2013): Afatinib (Giotrif®) for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s). DSD: Horizon Scanning in Oncology 41.

Breuer, J. and Nachtnebel, A. (2013): Enzalutamide (Xtandi®) for patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy . DSD: Horizon Scanning in Oncology 37.

Böhler, C.E.H. and Wolf, S. (2020): Lung Cancer Screening in Risk Groups: A Review-Update of the Economic Evidence (Part II). HTA-Projektbericht 132b.

Dental and Pharmaceutical Benefits Agency (TLV), EUnetHTA and Main Association of Austrian Social Security Institutions (HVB), EUnetHTA and Agency for Quality and Accreditation in Health Care and Social Welfare (AAZ), EUnetHTA (2018): Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). EUnetHTA report. DSD: Horizon Scanning in Oncology 77.

Erdos, J. and Fischer, S. (2018): High-intensity focused ultrasound for the treatment of prostate cancer. 1st Update 2018. Decision Support Document 37/ Update 2018.

Finnish Medicines Agency (FIMEA), EUnetHTA and Norwegian Medicines Agency (NoMA), EUnetHTA (2017): Midostaurin with standard chemotherapy in FLT3-Positive Acute Myeloid Leukaemia. EUnetHTA report. DSD: Horizon Scanning in Oncology 74.

Frühwirth, I. and Wolf, S. (2022): Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess individual breast cancer risk, their utility and applicability in a breast cancer screening programme. HTA-Projektbericht 145.

Fuchs, E. and Schmidt, L. (2020): Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer. Decision Support Document 122.

Fuchs, E. and Wolf, S. and Scrozynski, G. (2019): Cervical Carcinoma Prevention - Implementation of an HPV screening test for early detection of cervical cancer in Austria . HTA-Projektbericht 121.

Fuchs, S. and Grössmann, N. and Eckhardt, H. and Busse, R. and Wild, C. (2018): PET/PET-CT Evidence for need based planning in Germany and Austria. HTA-Projektbericht 77/ Update 2018.

Gassner, L. and Wild, C. and Hofer, V. (2022): Chemosaturation with percutaneous hepatic perfusion for patients with liver cancer. Decision Support Document 133.

Geiger-Gritsch, S. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: CAR-T Cell Therapy. AIHTA Policy Brief 006a.

Geiger-Gritsch, S. and Absenger, G. and Endel, F. and Flicker, M. and Hermann, A. and Kocher, F. and Olschewski, H. and Pall, G. and Wurm, M. and Zechmeister, M. (2021): Health Services Research in Oncology: Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Therapy in Real-World Practice. A Pilot Project in Cooperation with Tirol Kliniken GmbH & KAGes. HTA-Projektbericht 126.

Geiger-Gritsch, S. (2010): Bendamustine (Ribomustin®/Treanda®/ Levact®) for indolent non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma. DSD: Horizon Scanning in Oncology 10.

Glanz, K.A. (2021): Nivolumab in malignant melanoma: contrasting the evidence from pivotal trials with Real World Evidence (RWE). HTA-Projektbericht 140.

Goetz, G. (2021): Stool DNA testing for colorectal cancer (CRC) screening. AIHTA Policy Brief 011.

Goetz, G. and Mitic, M. (2018): Carbon ion beam radiotherapy (CIRT) for cancer treatment: a systematic review of effectiveness and safety for 12 oncologic indications. HTA-Projektbericht 101.

Grössmann, N. (2021): Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer. Update May 2021. Oncology Fact Sheet Nr. 36.

Grössmann, N. (2021): Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement. Update May 2021. Oncology Fact Sheet Nr. 40.

Grössmann, N. (2021): Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis. Update April 2021. Oncology Fact Sheet Nr. 33.

Grössmann, N. (2021): Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI-H or dMMR colorectal cancer. Update April 2021. Oncology Fact Sheet Nr. 34.

Grössmann, N. (2021): Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer. Update April 2021. Oncology Fact Sheet Nr. 37.

Grössmann, N. (2021): Duvelisib (Copiktra®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL). Update August 2021. Oncology Fact Sheet Nr. 44.

Grössmann, N. (2021): Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer. Update March 2021. Oncology Fact Sheet Nr. 32.

Grössmann, N. (2021): Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). Update August 2021. Oncology Fact Sheet Nr. 45.

Grössmann, N. (2021): Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). Update August 2021. Oncology Fact Sheet Nr. 46.

Grössmann, N. (2021): Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen. Update February 2021. Oncology Fact Sheet Nr. 8.

Grössmann, N. (2021): Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. Update February 2021. Oncology Fact Sheet Nr. 12.

Grössmann, N. (2021): Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC. Update February 2021. Oncology Fact Sheet Nr. 13.

Grössmann, N. (2021): Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL). Update February 2021. Oncology Fact Sheet Nr. 15.

Grössmann, N. (2021): Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Update February 2021. Oncology Fact Sheet Nr. 18.

Grössmann, N. (2021): Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). Update February 2021. Oncology Fact Sheet Nr. 19.

Grössmann, N. (2021): Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC). Update February 2021. Oncology Fact Sheet Nr. 20.

Grössmann, N. (2021): Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC). Update February 2021. Oncology Fact Sheet Nr. 21.

Grössmann, N. (2021): Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer. Update February 2021. Oncology Fact Sheet Nr. 22.

Grössmann, N. (2021): Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC). Update February 2021. Oncology Fact Sheet Nr. 23.

Grössmann, N. (2021): Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer. Update February 2021. Oncology Fact Sheet Nr. 24.

Grössmann, N. (2021): Blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL). Update February 2021. Oncology Fact Sheet Nr. 25.

Grössmann, N. (2021): Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC). Update February 2021. Oncology Fact Sheet Nr. 26.

Grössmann, N. (2021): Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM). Update February 2021. Oncology Fact Sheet Nr. 29.

Grössmann, N. (2021): A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer. Update February 2021. Oncology Fact Sheet Nr. 30.

Grössmann, N. (2021): Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Update August 2021. Oncology Fact Sheet Nr. 42.

Grössmann, N. (2021): Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM). Update August 2021. Oncology Fact Sheet Nr. 43.

Grössmann, N. (2020): Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma. Update February 2021. Oncology Fact Sheet Nr. 31.

Grössmann, N. (2020): Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL). Update February 2021. Oncology Fact Sheet Nr. 27.

Grössmann, N. (2020): Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Update July 2020. Oncology Fact Sheet Nr. 7.

Grössmann, N. (2020): Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma. Update July 2020. Oncology Fact Sheet Nr. 9.

Grössmann, N. (2020): Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML). Update July 2020. Oncology Fact Sheet Nr. 10.

Grössmann, N. (2020): Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer. Update July 2020. Oncology Fact Sheet Nr. 11.

Grössmann, N. (2020): Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions. Update July 2020. Oncology Fact Sheet Nr. 1.

Grössmann, N. (2020): Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC). Update July 2020. Oncology Fact Sheet Nr. 2.

Grössmann, N. (2020): Brigatinib (Alunbrig®) in ALK-positive non–small-cell lung cancer (NSCLC). Update July 2020. Oncology Fact Sheet Nr. 4.

Grössmann, N. (2020): Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM). Update July 2020. Oncology Fact Sheet Nr. 6.

Grössmann, N. (2020): Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL). Update July 2020. Oncology Fact Sheet Nr. 5.

Grössmann, N. (2020): Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL). Oncology Fact Sheet Nr. 14.

Grössmann, N. and Wild, C. (2020): Update PET/PET-CT evidence for need based planning in the area of oncology. AIHTA Policy Brief 003.

Grössmann, N. (2020): Rituximab (MabThera®) for the treatment of paediatric patients with previously untreated advanced stage CD20 positive DLBCL, BL, BAL, or BLL. Oncology Fact Sheet Nr. 3.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 39th Prioritisation – 2nd quarter 2019 . HSO: 39th Prioritisation.

Grössmann, N. (2017): Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC). DSD: Horizon Scanning in Oncology 75.

Grössmann, N. (2017): Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC). DSD: Horizon Scanning in Oncology 72.

Grössmann, N. (2017): Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC). DSD: Horizon Scanning in Oncology 70.

Grössmann, N. (2016): Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM). DSD: Horizon Scanning in Oncology 63.

Grössmann, N. (2016): Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion. DSD: Horizon Scanning in Oncology 62.

Grössmann, N. (2016): Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy. DSD: Horizon Scanning in Oncology 59.

Grössmann, N. (2016): Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL). DSD: Horizon Scanning in Oncology 60.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 41st Prioritisation – 4th quarter 2019. HSO: 41st Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 40th Prioritisation – 3rd quarter 2019. HSO: 40th Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 37th Prioritization – 4th quarter 2018. HSO: 37th Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 36th Prioritisation – 3rd quarter 2018. HSO: 36th Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 35th Prioritisation – 2nd quarter 2018. HSO: 35th Prioritisation.

Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 28th Prioritisation – 3rd quarter 2016. HSO: 28th Prioritisation.

Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 27th Prioritisation – 2nd quarter 2016 . HSO: 27th Prioritisation.

Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 26th Prioritisation – 1st quarter 2016. HSO: 26th Prioritisation.

Grössmann, N. and Wild, C. and Mayer, J. (2016): Drugs in Oncology: an overview of benefit and refund practices in Europe. Rapid Assessment 008.

Grössmann, N. and Wild, C. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 25th Prioritisation – 4th quarter 2015. HSO: 25th Prioritisation.

Grössmann, N. and Wolf, S. (2018): Horizon Scanning in Oncology 34th Prioritisation – 1st quarter 2018. HSO: 34th Prioritisation.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology 33rd Prioritisation – 4th quarter 2017. HSO: 33rd Prioritisation.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 32nd Prioritisation – 3rd quarter 2017. HSO: 32nd Prioritisation.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology 31st Prioritisation – 2nd quarter 2017 . HSO: 31st Prioritisation.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 30th Prioritisation – 1st quarter 2017. HSO: 30th Prioritisation.

Grössmann, N. and Wolf, S. (2017): Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy. DSD: Horizon Scanning in Oncology 66.

Grössmann, N. and Wolf, S. and Rothschedl, E. (2019): Horizon Scanning in Oncology 38th Prioritisation – 1st quarter 2019. HSO: 38th Prioritisation.

Grössmann, N. and Wolf, S. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 29th Prioritisation – 4th quarter 2016.. HSO: 29th Prioritisation.

Gugerbauer, J. and Warmuth, M. (2011): Radiofrequency ablation for hepatocellular carcinoma and colorectal liver metastases. Decision Support Document 049.

Haute Autorité de Santé (HAS), EUnetHTA and Autoridade Nacional do Medicamento e Productos de Saude (INFARMED), EUnetHTA (2017): Regorafenib indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have previously been treated with sorafenib. EUnetHTA report. DSD: Horizon Scanning in Oncology 73.

Hepperger, C. and Nachtnebel, A. (2014): Bevacizumab (Avastin®) for platinum-resistant recurrent, epithelial ovarian, fallopian tube or primary peritoneal cancer. DSD: Horizon Scanning in Oncology 48.

Hepperger, C. and Nachtnebel, A. (2011): S-1 (TeysunoTM) as first-line therapy for patients with advanced non-small cell lung cancer. DSD: Horizon Scanning in Oncology 19.

Hintringer, K. (2012): Brentuximab (Adcetris®) for the treatment of relapsed Hodgkin's lymphoma (HL) or relapsed systemic anaplastic large cell lymphoma (sALCL). DSD: Horizon Scanning in Oncology 26.

Hintringer, K. (2012): Romidepsin (Istodax®) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) after prior systemic therapy. DSD: Horizon Scanning in Oncology 25.

Hintringer, K. (2011): Panitumumab (Vectibix®) as 1st-line combination therapy for the treatment of WT KRAS metastatic colorectal cancer - 1st Update 2011. DSD: Horizon Scanning in Oncology 11 / Update 2011.

Hintringer, K. (2011): Dasatinib (Sprycel®) for the 1st-line treatment of Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase. DSD: Horizon Scanning in Oncology 17.

Hintringer, K. (2011): Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase. DSD: Horizon Scanning in Oncology 15.

Hintringer, K. (2010): Pazopanib (Votrient®) for the treatment of locally advanced and/or metastatic renal cell carcinoma. DSD: Horizon Scanning in Oncology 13.

Hintringer, K. (2010): Panitumumab (Vectibix ®) for the first-line treatment of metastatic colorectal cancer. DSD: Horizon Scanning in Oncology 11.

Hintringer, K. (2010): Plerixafor (Mozobil ®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma. DSD: Horizon Scanning in Oncology 08.

Hintringer, K. (2010): Trabectedin (Yondelis ®) for second-line recurrent platinum-sensitive ovarian cancer. DSD: Horizon Scanning in Oncology 07.

Hintringer, K. (2009): Cetuximab (Erbitux®) in EGFR-expressing Non-Small Cell Lung Cancer. DSD: Horizon Scanning in Oncology 02.

Jeitler, K. and Semlitsch , T. (2012): Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole. DSD: Horizon Scanning in Oncology 32.

Jeitler, K. and Semlitsch, T. (2012): Bevacizumab (Avastin®) in combination with chemotherapy in previously treated metastatic breast cancer. DSD: Horizon Scanning in Oncology 27.

Joppi, R and Nachtnebel, A. (2012): Trametinib for advanced or metastatic BRAF V600 mutation-positive melanoma. DSD: Horizon Scanning in Oncology 34.

Joppi, R. and Nachtnebel, A. (2012): Ipilimumab (Yervoy®) for the first-line therapy of advanced/metastatic cutaneous melanoma . DSD: Horizon Scanning in Oncology 30.

Joppi, R. and Wild, C. (2012): Vemurafenib for patients with BRAF V600E mutation positive advanced/metastatic melanoma. DSD: Horizon Scanning in Oncology 23.

Kirisits, A. and Wild, C. (2012): Efficacy of Hyperthermia Treatment in combination with radio- or chemotherapy in Breast-, Bladder-, Cervix Carcinoma and Soft Tissue Sarcoma patients. Update 2012. Decision Support Document 36 / Update 2012.

Kisser, A. and Kirisits, A. (2014): Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of peritoneal carcinomatosis . Decision Support Document 74.

Kisser, A. and Zechmeister-Koss, I. (2013): P16/Ki-67 Dual Stain in the triage of PAPIII/IIID cytology in cervical cancer screening . HTA-Projektbericht 72.

Mathis, S. and Eisner, W. (2010): Gamma Knife versus adapted linear accelerators: A comparison of two radiosurgical applications . HTA-Projektbericht 47.

Mathis, S. and Garbaty , T. and Czeczot , J. and Maran , P.R. and Alberti, C. and Nachtnebel, A. (2011): Eribulin (Halaven®) as third- or late- line mono-therapy for advanced/metastatic breast cancer. DSD: Horizon Scanning in Oncology 18.

Mathis, S. and Johansson, T. (2010): Hyperthermia. Decision Support Document 36.

Mayer-Ferbas, J. and Jeindl, R. (2024): Liposuction for the removal of subcutaneous (large) lipomas. Rapid Review Nr.: 009.

McGahan , L (2018): Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström’s macroglobulinaemia. DSD: Horizon Scanning in Oncology 85.

McGahan, L. (2019): Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 91.

McGahan, L. (2019): Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs). DSD: Horizon Scanning in Oncology 89.

McGahan, L. (2019): Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triple-negative breast cancer (aTNBC). DSD: Horizon Scanning in Oncology 87.

McGahan, L. (2018): Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 83.

McGahan, L. (2018): Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non–small-cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 80.

McGahan, L. (2018): Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC). DSD: Horizon Scanning in Oncology 78.

McGahan, L. (2017): Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small-cell lung cancer after prior chemoradiotherapy. DSD: Horizon Scanning in Oncology 76.

McGahan, L. (2017): Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer. DSD: Horizon Scanning in Oncology 71.

McGahan, L. (2017): Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer. DSD: Horizon Scanning in Oncology 69.

McGahan, L. (2017): Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 68.

McGahan, L. (2017): Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer. DSD: Horizon Scanning in Oncology 64.

McGahan, L. (2016): Atezolizumab (Tecentriq™) for the treatment of locally advanced and metastatic urothelial carcinoma. DSD: Horizon Scanning in Oncology 61.

Nachtnebel, A (2015): Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma. DSD: Horizon Scanning in Oncology 54.

Nachtnebel, A. (2014): Horizon Scanning in Oncology: Results of the 21st Prioritisation – 4th quarter 2014. HSO: 21st Prioritisation.

Nachtnebel, A. (2013): Pomalidomide (Pomalidomide Celgene/Pomalyst®) for the ≥ 3rd-line therapy of patients with relapsed and refractory multiple myeloma. DSD: Horizon Scanning in Oncology 39.

Nachtnebel, A. (2012): Pertuzumab (Omnitarg/Perjeta®) for the first-line therapy of metastatic HER2 positive breast cancer. DSD: Horizon Scanning in Oncology 31.

Nachtnebel, A. (2012): Erlotinib (Tarceva®) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations. DSD: Horizon Scanning in Oncology 22.

Nachtnebel, A. (2011): Rituximab (Rituxan®/MabThera®)for the first- and second-line treatment of chronic lymphocytic leukaemia - 1st Update 2011. DSD: Horizon Scanning in Oncology 04 / Update 2011.

Nachtnebel, A. (2011): Gefitinib (Iressa®) for the 1st-line treatment of non-small cell lung cancer – 1st Update 2011. DSD: Horizon Scanning in Oncology 06 / Update 2011.

Nachtnebel, A. (2011): Second-line chemotherapy with cabazitaxel (Jevtana®) for the treatment of castration-resistant metastatic prostate cancer. DSD: Horizon Scanning in Oncology 16.

Nachtnebel, A. (2011): Ipilimumab for pre-treated patients with advanced/metastatic melanoma . DSD: Horizon Scanning in Oncology 14.

Nachtnebel, A. (2010): Lapatinib ditosylate (Tyverb/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer. DSD: Horizon Scanning in Oncology 09.

Nachtnebel, A. (2010): Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer . DSD: Horizon Scanning in Oncology 06.

Nachtnebel, A. (2009): Everolimus (Afinitor®) for advanced/metastatic kidney cancer. DSD: Horizon Scanning in Oncology 03.

Nachtnebel, A. (2009): Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes. DSD: Horizon Scanning in Oncology 01.

Nachtnebel, A. (2009): Ibritumomab tiuxetan (Zevalin®) as consolidation therapy after first remission in patients with follicular lymphoma. DSD: Horizon Scanning in Oncology 05.

Nachtnebel, A. and Breuer, J. (2014): Ibrutinib (Imbruvica®) for relapsed or refractory chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 47.

Nachtnebel, A. and Maran , P.R. and Alberti, C. and Garbaty , T. and Czeczot , J. (2012): Lenalidomide (Revlimid®) for the treatment of low /intermediate-1 risk myelodysplastic syndrome with chromosome 5q deletion. DSD: Horizon Scanning in Oncology 28.

Nachtnebel, A. and Polkowska, M. and Czeczot , J. and Joppi, R. and Poggiani, C. (2013): Trastuzumab emtansine (Kadcyla™) for previously treated patients with HER2-positive advanced/metastatic breast cancer . DSD: Horizon Scanning in Oncology 36.

Nachtnebel, A. and Püntmann, I. (2011): Abiraterone acetate (Zytiga™) as 2nd-line therapy for the treatment of metastatic castration resistant prostate cancer after docetaxel therapy. DSD: Horizon Scanning in Oncology 20.

Nachtnebel, A. and Sotti, G. and Vitale, A. and Perrini, MR. (2011): Selective internal radiotherapy using yttrium-90 microspheres for primary and secondary liver malignancies. German version. Decision Support Document 47.

Nachtnebel, A. and Sotti, G. and Vitale, A. and Perrini, MR. (2011): Selective internal radiotherapy using yttrium-90 microspheres for primary and secondary liver malignancies. English version. Decision Support Document 47.

Nachtnebel, A. and Ujeyl, M. (2015): Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer. DSD: Horizon Scanning in Oncology 53.

Panhuber, A. and Titieni-Schuhmann, A. and Goetz, G. and Wild, C. (2022): CAR-T cell therapy: Contrasting the evidence from pivotal trials with the real world evidence (RWE). HTA-Projektbericht 146.

Patera, N. (2013): Screening for Colorectal Cancer. Part 3: Status of screening-activities and quality assurance of screening-colonoscopy. HTA-Projektbericht 41c.

Patera, N. (2011): Quality of care in oncology and its measurement. HTA-Projektbericht 49a.

Patera, N. (2010): Screening for Colorectal Cancer. Part 1: Screening-Tests and Project Design. (2nd revised edition). HTA-Projektbericht 41a.

Patera, N. and Schumacher, I. (2012): Screening for Colorectal Cancer. Part 1: Screening Tests and Program Design (3. updated edition). HTA-Projektbericht 41a.

Patera, N. and Schumacher, I. (2012): Screening for Colorectal Cancer. Part 2: Health economic evaluations and cost dynamics (2. updated edition). HTA-Projektbericht 41b.

Patera, N. and Wild, C. (2012): Generic indicators for process quality in oncological care: A compendium. HTA-Projektbericht 49b.

Patera, N. and Wild, C. (2009): Status quo mammography screening: evaluation results from organised programs. HTA-Projektbericht 035.

Poggiani, C. and Hintringer, K. (2012): Axitinib (AG013736, Inlyta®) for the second-line treatment of metastatic renal cell carcinoma (mRCC) . DSD: Horizon Scanning in Oncology 21.

Poggiani, C. and Nachtnebel, A. (2012): Lenalidomide (Revlimid®) for the first-line therapy of transplant-ineligible patients with multiple myeloma. DSD: Horizon Scanning in Oncology 33.

Radlberger, P. and Zechmeister, I. (2010): Screening for Colorectal Cancer. Part 2: Health economic evaluations and developments of costs. HTA-Projektbericht 41b.

Robausch, M. and Grössmann, N. (2020): Health Services Research in Oncology. Part I: End-of-Life Care . HTA-Projektbericht 127.

Rochet, E. and Stringer, D. and Gassner, L. and Vandepeer, M. and Forel, D. and Bachlani, A. and Duncan, J. (2022): Hepatic and portal vein embolisation prior to major hepatectomy. Decision Support Document 130.

Rothschedl, E. and Grössmann, N. (2024): Tislelizumab (Tizveni®) in monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Fact Sheet Nr. 164.

Rothschedl, E. and Grössmann, N. (2024): Retifanlimab (Zynyz®) as monotherapy for the first line treatment of patients with metastatic or recurrent locally advanced Merkel cell carcinoma. Fact Sheet Nr. 165.

Rothschedl, E. and Grössmann, N. (2024): Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM). Fact Sheet Nr. 166.

Rothschedl, E. and Grössmann, N. (2024): Pembrolizumab (Keytruda®) as pre- and post-operative treatment of resectable non small cell lung carcinoma (NSCLC). Fact Sheet Nr. 167.

Rothschedl, E. and Grössmann, N. (2024): Irinotecan hydrochloride trihydrate (Onivyde® pegylated liposomal) in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Fact Sheet Nr. 168.

Rothschedl, E. and Grössmann, N. (2024): Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours. Fact Sheet Nr. 169.

Rothschedl, E. and Grössmann, N. (2024): Enzalutamide (Xtandi®) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC). Fact Sheet Nr. 170.

Rothschedl, E. and Grössmann, N. (2024): Idecabtagene vicleucel (Abecma®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies. Fact Sheet Nr. 162.

Rothschedl, E. and Grössmann, N. (2024): Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer. Fact Sheet Nr. 163.

Rothschedl, E. and Grössmann, N. (2023): Avapritinib (Ayvakyt®) for the treatment of indolent systemic mastocytosis (ISM). Fact Sheet Nr. 157.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma (BTC). Fact Sheet Nr. 158.

Rothschedl, E. and Grössmann, N. (2023): Adagrasib (Krazati®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 159.

Rothschedl, E. and Grössmann, N. (2023): Momelotinib (Omjjara®) for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (PMF), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. Fact Sheet Nr. 160.

Rothschedl, E. and Grössmann, N. (2023): Talazoparib (Talzenna®) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Fact Sheet Nr. 161.

Rothschedl, E. and Grössmann, N. (2023): Zanubrutinib (Brukinsa®) with obinutuzumab for the treatment of refractory or relapsed follicular lymphoma (FL). Fact Sheet Nr. 151.

Rothschedl, E. and Grössmann, N. (2023): Elranatamab (Elrexfio®) as monotherapy for the treatment of relapsed and refractory multiple myeloma (MM). Fact Sheet Nr. 152.

Rothschedl, E. and Grössmann, N. (2023): Durvalumab (Imfinzi®) as monotherapy for the first line treatment of advanced or unresectable hepatocellular carcinoma (HCC). Fact Sheet Nr. 153.

Rothschedl, E. and Grössmann, N. (2023): Dostarlimab (Jemperli®) with carboplatin and paclitaxel for the treatment of mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) primary advanced or recurrent endometrial cancer (EC). Fact Sheet Nr. 154.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma. Fact Sheet Nr. 155.

Rothschedl, E. and Grössmann, N. (2023): Rucaparib (Rubraca®) as monotherapy for the maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. Fact Sheet Nr. 156.

Rothschedl, E. and Grössmann, N. (2023): Brentuximab vedotin (Adcetris®) in combination with doxorubicin, vinblastine and dacarbazine for previously untreated CD30+ Stage III or IV Hodgkin lymphoma. Update February 2024. Fact Sheet Nr. 146.

Rothschedl, E. and Grössmann, N. (2023): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation. Update April 2024. Fact Sheet Nr. 147.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of non-small cell lung carcinoma (NSCLC). Update April 2024. Fact Sheet Nr. 148.

Rothschedl, E. and Grössmann, N. (2023): Melphalan flufenamide (Pepaxti®) in combination with dexamethasone for the treatment of multiple myeloma (MM). Fact Sheet Nr. 149.

Rothschedl, E. and Grössmann, N. (2023): Quizartinib (Vanflyta®) in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, followed by single-agent maintenance therapy for patients with newly diagnosed acute myeloid leukaemia (AML). Update February 2024. Fact Sheet Nr. 150.

Rothschedl, E. and Grössmann, N. (2023): Crisantaspase (Enrylaze®) for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL). Update July/August 2023. Fact Sheet Nr. 138.

Rothschedl, E. and Grössmann, N. (2023): Cedazuridine/decitabine (Inaqovi®) for the treatment of newly diagnosed acute myeloid leukaemia (AML). Update December 2023. Fact Sheet Nr. 139.

Rothschedl, E. and Grössmann, N. (2023): Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer. Update December 2023. Fact Sheet Nr. 140.

Rothschedl, E. and Grössmann, N. (2023): Talquetamab (Talvey®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM). Update December 2023. Fact Sheet Nr. 141.

Rothschedl, E. and Grössmann, N. (2023): Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Update February 2024. Fact Sheet Nr. 142.

Rothschedl, E. and Grössmann, N. (2023): Tislelizumab (Tevimbra®) as monotherapy for the treatment of unresectable, locally advanced, or metastatic oesophageal squamous cell carcinoma (OSCC). Update February 2024. Fact Sheet Nr. 143.

Rothschedl, E. and Grössmann, N. (2023): Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease. Update July/August 2023. Fact Sheet Nr. 144.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Update July/August 2023. Fact Sheet Nr. 145.

Rothschedl, E. and Grössmann, N. (2023): Tremelimumab (Imjudo®) with durvalumab (Imfinzi®) and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC). Update October 2023. Fact Sheet Nr. 135.

Rothschedl, E. and Grössmann, N. (2023): Trifluridine/tipiracil (Lonsurf®, TAS-02) with bevacizumab for the treatment of metastatic colorectal cancer (CRC). Update October 2023. Fact Sheet Nr. 136.

Rothschedl, E. and Grössmann, N. (2023): Sacituzumab govitecan (Trodelvy®) for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer. Update October 2023. Fact Sheet Nr. 137.

Rothschedl, E. and Grössmann, N. (2023): Glofitamab (Columvi®) as monotherapy for the treatment of relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL). Update February 2024. Fact Sheet Nr. 130.

Rothschedl, E. and Grössmann, N. (2023): Pirtobrutinib (JaypircaTM) as monotherapy for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL). Update December 2023. Fact Sheet Nr. 131.

Rothschedl, E. and Grössmann, N. (2023): Ivosidenib (Tibsovo®) monotherapy for the treatment of locally advanced or metastatic cholangiocarcinoma. Update February 2024. Fact Sheet Nr. 127.

Rothschedl, E. and Grössmann, N. (2020): Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM). Update February 2024. Oncology Fact Sheet Nr. 17.

Rothschedl, E. and Wolf, S. (2023): Nivolumab (Opdivo®) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC). Update October 2023. Fact Sheet Nr. 133.

Rothschedl, E. and Wolf, S. (2023): Piflufolastat (18F) (Pylclari®) for the diagnosis of prostate cancer. Update October 2023. Fact Sheet Nr. 134.

Rothschedl, E. and Wolf, S. (2023): Futibatinib (Lytgobi®) for the treatment of locally advanced or metastatic cholangiocarcinoma. Update July 2023. Fact Sheet Nr. 132.

Rothschedl, E. and Wolf, S. (2023): Niraparib/abiraterone acetate (Akeega®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update July 2023. Fact Sheet Nr. 125.

Rothschedl, E. and Wolf, S. (2023): Ivosidenib (Tibsovo®, Tidhesco® ) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia (AML). Update June 2023. Fact Sheet Nr. 126.

Rothschedl, E. and Wolf, S. (2023): Cemiplimab (Libtayo®) in combination with platinum‐based chemotherapy for the first‐line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Update June 2023. Fact Sheet Nr. 128.

Rothschedl, E. and Wolf, S. (2023): Lisocabtagene maraleucel (Breyanzi®) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B). Update July 2023. Fact Sheet Nr. 129.

Rothschedl, E. and Wolf, S. (2023): Olaparib (Lynparza®) in combination with abiraterone and prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update April 2023. Oncology Fact Sheet Nr. 117.

Rothschedl, E. and Wolf, S. (2023): Tremelimumab (Imjudo®) in combination with durvalumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Update July 2023. Oncology Fact Sheet Nr. 118.

Rothschedl, E. and Wolf, S. (2023): Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC). Update April 2023. Oncology Fact Sheet Nr. 119.

Rothschedl, E. and Wolf, S. (2023): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer. Update April 2023. Oncology Fact Sheet Nr. 120.

Rothschedl, E. and Wolf, S. (2023): Nadofaragene firadenovec (Adstiladrin®) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours. Update June 2023. Fact Sheet Nr. 121.

Rothschedl, E. and Wolf, S. (2023): Oportuzumab monatox for the treatment of noninvasive urothelial carcinoma in situ (CIS) previously treated with Bacillus Calmette-Guérin (BCG). Update June 2023. Fact Sheet Nr. 122.

Rothschedl, E. and Wolf, S. (2023): Darolutamide (Nubeqa®) in combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of metastatic hormone‑sensitive prostate cancer (mHSPC). Update June 2023. Fact Sheet Nr. 123.

Rothschedl, E. and Wolf, S. (2022): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. Update April 2023. Oncology Fact Sheet Nr. 115.

Rothschedl, E. and Wolf, S. (2022): Durvalumab (Imfinzi®) in combination with gemcitabine and cisplatin for the first‑line treatment of unresectable or metastatic biliary tract cancer (BTC). Update April 2023. Oncology Fact Sheet Nr. 116.

Rothschedl, E. and Wolf, S. (2022): Zanubrutinib (Brukinsa®) as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL). Update March 2023. Fact Sheet Nr. 112.

Rothschedl, E. and Wolf, S. (2022): Cemiplimab (Libtayo®) as monotherapy for the treatment of recurrent or metastatic cervical cancer. Update March 2023. Fact Sheet Nr. 113.

Rothschedl, E. and Wolf, S. (2022): Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update April 2023. Oncology Fact Sheet Nr. 114.

Rothschedl, E. and Wolf, S. (2022): Loncastuximab tesirine (Zynlonta®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Update July 2023. Fact Sheet Nr. 109.

Rothschedl, E. and Wolf, S. (2022): Axicabtagene ciloleucel (Yescarta®) for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Update March 2023. Fact Sheet Nr. 111.

Rothschedl, E. and Wolf, S. (2022): Zanubrutinib (Brukinsa®) as monotherapy for the treatment of marginal zone lymphoma (MZL). Update March 2023. Fact Sheet Nr. 110.

Rothschedl, E. and Wolf, S. (2022): Relatlimab/nivolumab (Opdualag®) for the first line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%. Update December 2022. Oncology Fact Sheet Nr. 105.

Rothschedl, E. and Wolf, S. (2022): Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). Update December 2022. Oncology Fact Sheet Nr. 106.

Rothschedl, E. and Wolf, S. (2022): Teclistamab (Tecvayli®) as monotherapy for the treatment of patients with relapsed and refractory multiple myeloma (MM) who have received at least three prior therapies. Update December 2022. Oncology Fact Sheet Nr. 107.

Rothschedl, E. and Wolf, S. (2022): Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC). Update March 2023. Fact Sheet Nr. 108.

Rothschedl, E. and Wolf, S. (2022): Melphalan flufenamide (Pepaxti®) with dexamethasone for the treatment of multiple myeloma (MM). Update October 2022. Oncology Fact Sheet Nr. 100.

Rothschedl, E. and Wolf, S. (2022): Asciminib (Scemblix®) for the treatment of Philadelphia chromosome‑positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase (CP). Update November 2022. Oncology Fact Sheet Nr. 101.

Rothschedl, E. and Wolf, S. (2022): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer. Update November 2022. Oncology Fact Sheet Nr. 102.

Rothschedl, E. and Wolf, S. (2022): Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). Update November 2022. Oncology Fact Sheet Nr. 103.

Rothschedl, E. and Wolf, S. (2022): Olaparib (Lynparza®) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer. Update December 2022. Oncology Fact Sheet Nr. 104.

Rothschedl, E. and Wolf, S. (2022): Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer. Oncology Fact Sheet Nr. 65.

Rothschedl, E. and Wolf, S. (2022): Degarelix (Firmagon®) for treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy. Oncology Fact Sheet Nr. 66.

Rothschedl, E. and Wolf, S. (2022): Selinexor (Nexpovio®) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma (MM). Update October 2022. Oncology Fact Sheet Nr. 98.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma who have undergone complete resection. Update October 2022. Oncology Fact Sheet Nr. 99.

Rothschedl, E. and Wolf, S. (2022): Mosunetuzumab (Lunsumio®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL) Update September 2022. Oncology Fact Sheet Nr. 92.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) in combination with chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, for the treatment of locally advanced, or early‑stage triple‑negative breast cancer (TNBC). Update September 2022. Oncology Fact Sheet Nr. 94.

Rothschedl, E. and Wolf, S. (2022): Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced RET fusion positive non-small cell lung cancer (NSCLC). Update December 2022. Oncology Fact Sheet Nr. 95.

Rothschedl, E. and Wolf, S. (2022): Atezolizumab (Tecentriq®) as adjuvant treatment following complete resection and platinum-based chemotherapy for patients with non-small cell lung cancer (NSCLC). Update September 2022. Oncology Fact Sheet Nr. 96.

Rothschedl, E. and Wolf, S. (2022): Axicabtagene ciloleucel (Yescarta®) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). Update September 2022. Oncology Fact Sheet Nr. 97.

Rothschedl, E. and Wolf, S. (2022): Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM). Update June 2022. Oncology Fact Sheet Nr. 86.

Rothschedl, E. and Wolf, S. (2022): Cabozantinib (Cabometyx®) as monotherapy for the treatment of locally advanced or metastatic differentiated thyroid carcinoma (DTC). Update June 2022. Oncology Fact Sheet Nr. 87.

Rothschedl, E. and Wolf, S. (2022): Tisagenlecleucel (Kymriah®) for the treatment of relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Update July 2022. Oncology Fact Sheet Nr. 88.

Rothschedl, E. and Wolf, S. (2022): Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL). Update July 2022. Oncology Fact Sheet Nr. 89.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the treatment of microsatellite instability-high (MSI‑H) or mismatch repair deficient (dMMR) tumours in adults with unresectable or metastatic colorectal cancer, advanced or recurrent endometrial carcinoma and unresectable or metastatic gastric, small intestine, or biliary cancer. Update July 2022. Oncology Fact Sheet Nr. 90.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for the treatment of persistent, recurrent, or metastatic cervical cancer. Update July 2022. Oncology Fact Sheet Nr. 91.

Rothschedl, E. and Wolf, S. (2022): Tebentafusp (Kimmtrak®) as monotherapy for the treatment of human leukocyte antigen (HLA) A*02:01 positive patients with unresectable or metastatic uveal melanoma. Update March 2023. Fact Sheet Nr. 79.

Rothschedl, E. and Wolf, S. (2022): Relugolix (Orgovyx®) for the treatment of advanced hormone-sensitive prostate cancer. Update November 2022. Oncology Fact Sheet Nr. 80.

Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of muscle-invasive urothelial carcinoma (MIUC). Update June 2022. Oncology Fact Sheet Nr. 81.

Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) in combination with chemotherapy for the first-line treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). Update June 2022. Oncology Fact Sheet Nr. 83.

Rothschedl, E. and Wolf, S. (2022): Abemaciclib (Verzenios®) in combination with endocrine therapy for the adjuvant treatment of early breast cancer. Update June 2022. Oncology Fact Sheet Nr. 84.

Rothschedl, E. and Wolf, S. (2022): Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer. Update June 2022. Oncology Fact Sheet Nr. 85.

Rothschedl, E. and Wolf, S. (2022): Lisocabtagene maraleucel (Breyanzi®) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B). Update May 2022. Oncology Fact Sheet Nr. 77.

Rothschedl, E. and Wolf, S. (2022): Avapritinib (Ayvakyt®) for the treatment of advanced systemic mastocytosis (AdvSM). Update September 2022. Oncology Fact Sheet Nr. 78.

Rothschedl, E. and Wolf, S. (2022): Tepotinib (Tepmetko®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC). Update May 2022. Oncology Fact Sheet Nr. 73.

Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). Update June 2022. Oncology Fact Sheet Nr. 82.

Rothschedl, E. and Wolf, S. (2022): Capmatinib (Tabrecta®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). Update October 2022. Oncology Fact Sheet Nr. 93.

Rothschedl, E. and Wolf, S. (2021): Sotorasib (Lumykras®): Sotorasib (Lumykras®) as monotherapy for the treatment of advanced NSCLC with KRAS G12C mutation. Update May 2022. Oncology Fact Sheet Nr. 71.

Rothschedl, E. and Wolf, S. (2021): Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST). Update May 2022. Oncology Fact Sheet Nr. 62.

Rothschedl, E. and Wolf, S. (2021): Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM). Update November 2022. Oncology Fact Sheet Nr. 39.

Rothschedl, E. and Wolf, S. and Grössmann, N. (2021): Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL). Withdrawal of the marketing authorisation in the European Union. Update November 2022. Oncology Fact Sheet Nr. 35.

Rothschedl, E. and Wolf, S. and Grössmann, N. (2021): Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST). Update September 2022. Oncology Fact Sheet Nr. 16.

Rothschedl, E and Nachtnebel, A (2015): Carfilzomib (Kyprolis®) for patients with relapsed multiple myeloma who have received one to three prior lines of therapy . DSD: Horizon Scanning in Oncology 52.

Rothschedl, E. (2019): Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC). DSD: Horizon Scanning in Oncology 90.

Rothschedl, E. (2019): Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 88.

Rothschedl, E. (2019): Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer. DSD: Horizon Scanning in Oncology 86.

Rothschedl, E. (2018): Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 84.

Rothschedl, E. (2018): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC. DSD: Horizon Scanning in Oncology 82.

Rothschedl, E. (2018): Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma. DSD: Horizon Scanning in Oncology 81.

Rothschedl, E. (2018): Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL). DSD: Horizon Scanning in Oncology 79.

Rothschedl, E. and Joppi, R. and Poggiani, C. (2014): Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 49.

Rothschedl, E. and Nachtnebel, A. (2016): Bevacizumab (Avastin®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer. DSD: Horizon Scanning in Oncology 56.

Rothschedl, E. and Nachtnebel, A. (2015): Pembrolizumab (Keytruda®) for the treatment of advanced melanoma. DSD: Horizon Scanning in Oncology 55.

Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 24th Prioritisation – 3rd quarter 2015. HSO: 24th Prioritisation.

Rothschedl, E. and Nachtnebel, A. (2015): Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy. DSD: Horizon Scanning in Oncology 51.

Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology 23rd Prioritisation – 2nd quarter 2015. HSO: 23rd Prioritisation.

Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 22nd Prioritisation – 1st quarter 2015. HSO: 22nd Prioritisation.

Rothschedl, E. and Nachtnebel, A. (2014): Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma. DSD: Horizon Scanning in Oncology 46.

Rothschedl, E. and Nachtnebel, A. (2013): Regorafenib (Stivarga®) for heavily pretreated patients with metastatic colorectal cancer (mCRC). DSD: Horizon Scanning in Oncology 40.

Rothschedl, E. and Nachtnebel, A. (2013): Aflibercept (Zaltrap®) in addition to FOLFIRI for the 2nd line therapy of metastatic colorectal cancer. DSD: Horizon Scanning in Oncology 38.

Schiller-Frühwirth, I. and Wild, C. and Geiger-Gritsch, S. and Mittermayr, T. (2009): Intraoperative radiotherapy for primary breast cancer. Systematic Review.. Decision Support Document 23.

Schiller-Frühwirth, I. and Wild, C. (2012): Intraoperative radiotherapy for primary breast cancer. Decision Support Document 23 / Update 2012.

Schmidt, L. and Lohr, P. and Wild, C. (2018): Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer. HTA-Projektbericht 107.

Schott, G. (2010): Trastuzumab (Herceptin®) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer. DSD: Horizon Scanning in Oncology 12.

Sehic, O. and Wild, C. (2022): ATMPs and Gene Therapies in Development. Horizon Scanning – Update 2022. AIHTA Policy Brief 006b/ 1. Update.

Sehic, O. and Wild, C. (2022): CAR-T Cell-Therapies in Development, Update 2022. AIHTA Policy Brief 006a/ 1. Update.

Semlitsch, T. and Jeitler, K. and Zipp, C. and Krenn, C. and Horvath, K. and Zens, Y. and Hausner, E. and Sauerland, S. and Störchel, M. and Sturtz, S. and Varela Lema, L. and Paz Valiñas, L. and Puñal Riobóo, J. and Cantero Muñoz, P. and Faraldo Vallés, M.J. (2020): Lung cancer screening in risk groups. HTA-Projektbericht 132a.

Semlitsch , T. and Jeitler, K. (2013): Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) . DSD: Horizon Scanning in Oncology 35.

Semlitsch, T. and Zengerer, A. and Jeitler, K. (2014): Nab-Paclitaxel (Abraxane®) as first-line therapy for metastatic adenocarcinoma of the pancreas. DSD: Horizon Scanning in Oncology 43.

Semlitsch, T. and Zengerer, A. and Jeitler, K. (2013): Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma. DSD: Horizon Scanning in Oncology 42.

Stanak, M. and Grössmann, N. and Strohmaier, C. (2019): 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer . Decision Support Document 118.

Ujeyl, M. (2012): Everolimus (Afinitor®) for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin. DSD: Horizon Scanning in Oncology 24.

Ujeyl, M. and Nachtnebel, A. (2015): Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma. DSD: Horizon Scanning in Oncology 50.

Van der Vossen, A. (2013): Marketing Authorisations under Exceptional Circumstances for Oncology Drugs . HTA- Projektbericht 65.

Vandepeer, M. and Forel, D. and Nicolopoulos, K. and Rochet, E. and Ali, A. and Duncan, J. and Goetz, G. (2022): Microwave ablation for liver tumours. Decision Support Document 131.

Warmuth, M. (2009): Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 04.

Warmuth, M. and Johansson, T. (2010): High-intensity focussed ultrasound (HIFU) for the treatment of prostate cancer. Decision Support Document 37.

Wild, C. and Sehic, O. (2020): Proton and carbon ion therapy - an update on indications. AIHTA Policy Brief 004.

Wild, C. and Wohlhöfner, K. and Sehic, O. and Grössmann, N. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: ATMPs and Gene Therapies. AIHTA Policy Brief 006b.

Wild, C. (2005): [Hyperthermia in the treatment of malignant tumours]. HTA-Newsletter 34: p. 2.

Wild, C. (2004): [Home-based chemotherapy: Evaluation criteria]. HTA-Newsletter 30: p. 4.

Wild, C. (2002): [New anti-cancer drugs]. ITA-Newsletter December 2002: p. 9.

Wild, C. (2002): [Proton radiation]. HTA-Newsletter 11: p. 2.

Wild, C. (2001): [Erythropoietin for anaemic tumour patients]. HTA-Newsletter 01: p. 2.

Wild, C. (2000): [EPO for cancer related anaemia]. ITA-Newsletter April 2000: p. 5.

Wild, C. and Jonas, S. (2000): [EPO in cancer anaemia]. ITA-Newsletter September 2000: pp. 2-3.

Wild, C. and Jonas, S. (2000): [Erythropoietin in tumour anaemia. An assessment]. ITA-Projektbericht 15.

Wild, C. (2015): Hadron therapy in children: evidence synthesis for 15 paediatric tumours. Report based on Belgian (KCE) HTA report. Decision Support Document 88.

Wild, C. (2006): [Proton therapy]. ÖKZ: Österreichische Krankenhauszeitung 47 (03): p. 19.

Wild, C. (2002): Erythropoietin in tumor anemia - for whom is effective?. International Journal of Cancer 13 (Supplement): p. 70.

Wild, C. (2001): [Assessing medical interventions: Erythropoietin in tumour anaemia]. TA-Datenbank-Nachrichten (01, Sonderheft): pp. 51-55.

Wild, C. and Grössmann, N. (2019): FoundationOne®CDx: genetic profiling of solid tumours. Rapid Assessment 014.

Wild, C. and Hintringer, K. and Narath, M. (2013): Hadron therapy: Proton and carbon ion therapy - A review of clinical evidence of efficacy, ongoing research and reimbursement. HTA-Projektbericht 74.

Wild, C. and Jonas, S. (2001): [Health policy decisions between rationing and rationalisation as demonstrated by the example of erythropoietin in tumour anaemia]. Das Gesundheitswesen 63 (2): pp. 221-225.

Wild, C. and Jonas, S. (2000): [Erythropoietin (EPO) in tumour anaemia]. Newsletter der Österreichischen Gesellschaft für Public Health (4): pp. 1-2.

Wild, C. and Patera, N. (2014): Stereotactic Radiofrequency ablation/ SRFA for hepatocellular carcinoma and liver metastases. Decision Support Document 76.

Wild, C. and Patera, N. and Küllinger, R. and Narath, M. (2015): PET/PET-CT Evidence for need based planning (in oncology indications). HTA-Projektbericht 77.

Wolf, S. (2022): Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer. Oncology Fact Sheet Nr. 72.

Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of renal cell carcinoma (RCC). Update March 2022. Oncology Fact Sheet Nr. 74.

Wolf, S. (2022): Lorlatinib (Lorviqua®) as monotherapy for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC). Update March 2022. Oncology Fact Sheet Nr. 75.

Wolf, S. (2022): Tegafur/gimeracil/oteracil (Teysuno®) for the treatment of metastatic colorectal cancer. Update March 2022. Oncology Fact Sheet Nr. 76.

Wolf, S. (2021): Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC). Update January 2022. Oncology Fact Sheet Nr. 67.

Wolf, S. (2021): Pembrolizumab (Keytruda) in combination with Lenvatinib (Lenvima®) for the treatment of advanced or recurrent endometrial carcinoma (EC). Update February 2022. Oncology Fact Sheet Nr. 68.

Wolf, S. (2021): Amivantamab (Rybrevant®) as monotherapy for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations. Update March 2022. Oncology Fact Sheet Nr. 69.

Wolf, S. (2021): Sacituzumab govitecan (Trodelvy) as monotherapy for the treatment of patients with unresectable or metastatic triple-negative breast cancer (mTNBC). Update January 2022. Oncology Fact Sheet Nr. 70.

Wolf, S. (2021): Zanubrutinib (Brukinsa®) as monotherapy for the treatment of patients with Waldenström's Macroglobulinaemia (WM). Update February 2022. Oncology Fact Sheet Nr. 60.

Wolf, S. (2021): Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC). Update March 2022. Oncology Fact Sheet Nr. 61.

Wolf, S. (2021): Nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the treatment of patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma. Update February 2022. Oncology Fact Sheet Nr. 63.

Wolf, S. (2021): Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC). Update February 2022. Oncology Fact Sheet Nr. 64.

Wolf, S. (2021): Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL). Update July 2021. Oncology Fact Sheet Nr. 38.

Wolf, S. (2021): Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC). Update March 2022. Oncology Fact Sheet Nr. 41.

Wolf, S. (2021): Idecabtagene vicleucel (Abecma®) for the treatment of patients with relapsed and refractory multiple myeloma (MM). Update September 2021. Oncology Fact Sheet Nr. 57.

Wolf, S. (2021): Tafasitamab (Minjuvi®; Monjuvi®) for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). Update November 2021. Oncology Fact Sheet Nr. 58.

Wolf, S. (2021): Adjuvant nivolumab (Opdivo®) as monotherapy for the treatment of patients with oesophageal (OC) or gastro-oesophageal junction cancer (GEJC). Update November 2021. Oncology Fact Sheet Nr. 59.

Wolf, S. (2021): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer. Update September 2021. Oncology Fact Sheet Nr. 51.

Wolf, S. (2021): Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC). Update September 2021. Oncology Fact Sheet Nr. 52.

Wolf, S. (2021): Cemiplimab (Libtayo®) as monotherapy for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC). Update September 2021. Oncology Fact Sheet Nr. 53.

Wolf, S. (2021): Pembrolizumab (Keytruda®) in combination with platinum and fluoropyrimidine based chemotherapy for the treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus. Update August 2021. Oncology Fact Sheet Nr. 54.

Wolf, S. (2021): Daratumumab (Darzalex®) in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma (MM). Update September 2021. Oncology Fact Sheet Nr. 55.

Wolf, S. (2021): Daratumumab (Darzalex®) in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of newly diagnosed systemic light chain (AL) amyloidosis. Update September 2021. Oncology Fact Sheet Nr. 56.

Wolf, S. (2021): Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML). Update August 2021. Oncology Fact Sheet Nr. 47.

Wolf, S. (2021): Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC). Update August 2021. Oncology Fact Sheet Nr. 48.

Wolf, S. (2021): Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML). Update August 2021. Oncology Fact Sheet Nr. 49.

Wolf, S. (2021): Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma. Update August 2021. Oncology Fact Sheet Nr. 50.

Wolf, S. (2020): Tagraxofusp (Elzonris®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN). Update March 2022. Oncology Fact Sheet Nr. 28.

Wolf, S. and Al Froukh, R.F. (2023): 177Lu-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Systematic Review. 1st Update 2023. Decision Support Document 118/ Update 2023.

Wolf, S. and Grössmann, N. (2020): Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble). Decision Support Document 123.

Wolf, S. (2017): Ipilimumab (Yervoy®) in the adjuvant therapy for high-risk stage III cutaneous melanoma. DSD: Horizon Scanning in Oncology 67.

Wolf, S. and Grössmann, N. (2017): Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer. DSD: Horizon Scanning in Oncology 65.

Zapata Cachafeiro, M. and Varela Lema, L. and Faraldo Vallés, M.J. and Fuchs, E. (2019): Irreversible electroporation for the treatment of liver and pancreatic cancer. HTA-Projektbericht 119.

Zorginstituut Nederland (ZIN), EUnetHTA and Belgian Health Care Knowledge Centre (KCE), EUnetHTA (2018): MammaPrint® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer. EUnetHTA report . HTA-Projektbericht 102.